Cambridge University Researchers Trial AI-Designed Vaccine Against All Coronaviruses in Humans
A research team at the University of Cambridge has pioneered a new class of vaccine, with its critical component designed entirely by artificial intelligence. This vaccine aims to confer protection against all coronaviruses, encompassing existing COVID-19 variants and those animal viruses that could trigger future pandemics. Initial human trials have commenced, representing a significant shift in vaccine development methodology.
Professor Jonathan Heeney, leading the Cambridge team, highlighted the conventional vaccine development process as inherently reactive, consistently lagging behind viral mutations. The AI-driven approach seeks to pre-empt viral evolution, offering protection against unforeseen outbreaks. The AI analysed genetic sequences from various coronaviruses identified through surveillance programmes to design a "super-antigen". This antigen is intended to train the immune system to recognise and combat the entire viral family, even in the event of mutation or interspecies transmission.
The preliminary human trials involved 39 participants, primarily to assess the vaccine's safety profile. A subsequent study with approximately 200 individuals is planned to further evaluate its efficacy in eliciting an immune response. Findings published in the Journal of Infection described a "modest" impact on the immune system, yet the technology has generated considerable interest.
Professor Saul Faust, who conducted parts of the trial at the University of Southampton, affirmed the "definite potential" of the AI design, particularly for developing vaccines resilient to the rapid mutation rates of pandemic-prone viruses. Beyond coronaviruses, the Cambridge researchers are also exploring universal seasonal influenza vaccines and a preventative measure against H5N1 avian influenza, alongside a vaccine for viral haemorrhagic fevers, including Ebola species for which no current vaccine exists against some outbreaks.
Professor Andy Pollard, Director of the Oxford Vaccine Group, noted the "fascinating data" emerging from animal research using this approach, suggesting the AI's capability to generate unexpected immune responses. He emphasised that human trials remain the ultimate arbiter, given the complexities of the human immune system shaped by years of natural infections. Pollard added that AI tools are poised to revolutionise vaccine research, potentially accelerating development timelines and thereby saving lives.
